. 2020 Mar 12;6(1):21–31. doi: 10.1089/pancan.2019.0018

Table 2.

Most Common (≥10%) Treatment-Emergent Adverse Events Related to Study Treatment

	DURV1500-LY 20 mg/day (N = 3)^a			DURV1500-LY 30 mg/day (N = 3)^a			DURV1500-LY 40 mg/day (N = 3)^a			Total (N = 9)
Event (n, %)	Grade 1–2	Grade ≥3	Any grade	Grade 1–2	Grade ≥3	Any grade	Grade 1–2	Grade ≥3	Any grade	Grade 1–2	Grade ≥3	Any grade
Injection-site reaction	1 (33.3)	0 (0)	1 (33.3)	1 (33.3)	0 (0)	1 (33.3)	2 (66.7)	0 (0)	2 (66.7)	4 (44.4)	0 (0)	4 (44.4)
Fatigue	0 (0)	0 (0)	0 (0)	2 (66.7)	0 (0)	2 (66.7)	1 (33.3)	0 (0)	1 (33.3)	3 (33.3)	0 (0)	3 (33.3)
White blood cell count increased	2 (66.7)	0 (0)	2 (66.7)	1 (33.3)	0 (0)	1 (33.3)	0 (0)	0 (0)	0 (0)	3 (33.3)	0 (0)	3 (33.3)
Decreased appetite	0 (0)	0 (0)	0 (0)	2 (66.7)	0 (0)	2 (66.7)	0 (0)	0 (0)	0 (0)	2 (22.2)	0 (0)	2 (22.2)
Back pain	0 (0)	0 (0)	0 (0)	1 (33.3)	0 (0)	1 (33.3)	1 (33.3)	0 (0)	1 (33.3)	2 (22.2)	0 (0)	2 (22.2)
Hypothyroidism	0 (0)	0 (0)	0 (0)	1 (33.3)	0 (0)	1 (33.3)	1 (33.3)	0 (0)	1 (33.3)	2 (22.2)	0 (0)	2 (22.2)
Constipation	0 (0)	0 (0)	0 (0)	2 (66.7)	0 (0)	2 (66.7)	0 (0)	0 (0)	0 (0)	2 (22.2)	0 (0)	2 (22.2)
Nausea	0 (0)	0 (0)	0 (0)	2 (66.7)	0 (0)	2 (66.7)	0 (0)	0 (0)	0 (0)	2 (22.2)	0 (0)	2 (22.2)
Leukocytosis	0 (0)	0 (0)	0 (0)	0 (0)	1 (33.3)	1 (33.3)	0 (0)	0 (0)	0 (0)	0 (0)	1 (11.1)	1 (11.1)
Neutropenia	0 (0)	0 (0)	0 (0)	0 (0)	1 (33.3)	1 (33.3)	0 (0)	0 (0)	0 (0)	0 (0)	1 (11.1)	1 (11.1)
Pancreatic carcinoma metastatic^b	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (33.3)	1 (33.3)	0 (0)	1 (11.1)	1 (11.1)

^{^a}

Dose of durvalumab kept constant at 1500 mg every 4 weeks for all cohorts.

^{^b}

Nodules in injection area defined as metastases by investigator. See the Safety section for details.

DURV, durvalumab; LY, LY2510924.